Table 5. Age-Adjusted Incidence and Age- and Multivariable-Adjusted HRs and Their 95% CIs for the Development of Lacunar and Nonlacunar Infarctions According to Glucose Tolerance Levels Defined by the WHO Criteria

	WHO Criteria	Person-Years	No. of Events	Age-Adjusted Incidence per 1000 Person-Years	Age-Adjusted HR (95% CI)	P	Multivariable-Adjusted HR (95% CI)	P
Lacunar infarction								
Men	NGT	7397	14	2.3	1 (referent)		1 (referent)	
	Hyperglycemia	4863	13	2.7	1.19 (0.56 to 2.54)	0.65	0.99 (0.45 to 2.18)	0.99
	IFG	987	1	1.0	0.44 (0.06 to 3.38)	0.43	0.43 (0.06 to 3.28)	0.41
	IGT	2183	6	2.7	1.19 (0.46 to 3.11)	0.72	0.91 (0.32 to 2.57)	0.86
	Diabetes	1694	6	3.6	1.64 (0.63 to 4.28)	0.31	1.44 (0.54 to 3.86)	0.47
Women	NGT	11 769	19	2.0	1 (referent)		1 (referent)	
	Hyperglycemia	5600	23	3.8	1.97 (1.07 to 3.65)	0.03	1.62 (0.85 to 3.11)	0.14
	IFG	807	4	4.8	2.42 (0.82 to 7.13)	0.11	2.02 (0.67 to 6.09)	0.21
	IGT	3224	8	2.1	1.21 (0.53 to 2.78)	0.66	1.04 (0.44 to 2.43)	0.94
	Diabetes	1569	11	6.7	3.26 (1.54 to 6.89)	0.002	2.65 (1.19 to 5.93)	0.02
Nonlacunar infarction								
Men	NGT	7397	15	2.3	1 (referent)		1 (referent)	
	Hyperglycemia	4863	19	3.9	1.74 (0.88 to 3.42)	0.11	1.67 (0.83 to 3.37)	0.15
	IFG	987	1	0.9	0.45 (0.06 to 3.44)	0.44	0.41 (0.05 to 3.12)	0.39
	IGT	2183	5	2.3	1.00 (0.36 to 2.76)	1.00	0.91 (0.33 to 2.57)	0.87
	Diabetes	1694	13	7.7	3.44 (1.63 to 7.23)	0.001	3.78 (1.74 to 8.19)	0.001
Women	NGT	11 769	16	1.7	1 (referent)		1 (referent)	
	Hyperglycemia	5600	13	1.9	1.18 (0.57 to 2.47)	0.66	1.01 (0.46 to 2.20)	0.99
	IFG	807	3	3.1	1.94 (0.56 to 6.67)	0.29	1.78 (0.50 to 6.38)	0.38
	IGT	3224	5	1.3	0.80 (0.29 to 2.18)	0.66	0.70 (0.25 to 1.98)	0.51
	Diabetes	1569	5	2.6	1.58 (0.58 to 4.32)	0.37	1.26 (0.43 to 3.69)	0.67

Multivariable adjustment was made for age, systolic blood pressure, electrocardiogram abnormalities, body mass index, total and high-density lipoprotein cholesterol, smoking habits, alcohol intake, and regular exercise.
WHO indicates World Health Organization.

tolerance status was based on a single measurement of glucose levels at baseline as was the case in most other epidemiological studies. During the follow-up, risk factor levels were changed due to modifications in lifestyle or medication, and misclassification of glucose tolerance categories was possible. This could have weakened the association found in this study, biasing the results toward the null hypothesis. Therefore, the true association may be stronger than that shown in our study.

In conclusion, diabetes defined by an OGTT was an independent risk factor for cardiovascular disease, except for CHD in men. Notably, the new range in the 2003 American Diabetes Association criteria for IFG (FPG of 5.6 to 6.0 mmol/L) was not associated with ischemic stroke or CHD in either sex. The IFG category of the 1997 criteria (FPG of 6.1 to 6.9 mmol/L) increased the risk of ischemic stroke in women, although this association was not independent of other known risk factors. Because the risks of stroke and CHD and the prevalence of diabetes differ among races, further investigations are required to clarify the relationship between hyperglycemia and type of cardiovascular disease in other ethnic populations.

Sources of Funding

Disclosures

None.

References

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham Study. *JAMA*. 1979;241:2035–2038.
2. Tuomilehto J, Rastenyte D, Jousilahti P, Sarti C, Vartiainen E. Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population. *Stroke*. 1996;27:210–215.
3. Park S, Barrett-Connor E, Wingard DL, Shan J, Edelstein S. GHb is a better predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women without diabetes: the Rancho Bernardo Study. *Diabetes Care*. 1996;19:450–456.
4. Fujishima M, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, Ohmori S, Yoshitake T. Diabetes and cardiovascular disease in a prospective population survey in Japan: the Hisayama Study. *Diabetes*. 1996;45(suppl 3):S14–S16.
5. Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men: the Chicago Heart Association Detection Project in Industry Study. *Diabetes Care*. 1997;20:163–169.
6. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. *Diabetes Care*. 1999;22:920–924.

7. Barzilay JI, Spiekerman CF, Wahl PW, Kuller LH, Cushman M, Furberg CD, Dobs A, Polak JF, Savage PJ. Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. *Lancet*. 1999;354: 622–625.

8. The DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. *Arch Intern Med*. 2001; 161:397–405.

9. Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL. Postchallenge hyperglycemia and mortality in a national sample of US adults. *Diabetes Care*. 2001;24:1397–1402.

10. Smith NL, Barzilay JI, Shaffer D, Savage PJ, Heckbert SR, Kuller LH, Kronmal RA, Resnick HE, Psaty BM. Fasting and 2-hour postchallenge serum glucose measures and risk of incident cardiovascular events in the elderly: the Cardiovascular Health Study. *Arch Intern Med*. 2002;162: 209–216.

11. Wen CP, Cheng TY, Tsai SP, Hsu HL, Wang SL. Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan. *Diabetes Care*. 2005;28:2756–2761.

12. Kanaya AM, Herrington D, Vittinghoff E, Lin F, Bittner V, Cauley JA, Hulley S, Barrett-Connor E. Impaired fasting glucose and cardiovascular outcomes in postmenopausal women with coronary artery disease. *Ann Intern Med*. 2005;142:813–820.

13. Zhang Y, Galloway JM, Welty TK, Wiebers DO, Whisnant JP, Devereux RB, Kizer JR, Howard BV, Cowan LD, Yeh J, Howard WJ, Wang W, Best L, Lee ET. Incidence and risk factors for stroke in American Indians: the Strong Heart Study. *Circulation*. 2008;118:1577–1584.

14. Ohmura T, Ueda K, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, Nomiyama K, Ohmori S, Yoshitake T, Shinkawa A, Hasuo Y, Fujishima M. Prevalence of type 2 (non-insulin-dependent) diabetes mellitus and impaired glucose tolerance in the Japanese general population: the Hisayama Study. *Diabetologia*. 1993;36:1198–1203.

15. Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. *Stroke*. 1990;21: 637–676.

16. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med*. 1998;15:539–553.

17. Qiao Q, Jousilahti P, Eriksson J, Tuomilehto J. Predictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow-up. *Diabetes Care*. 2003;26:2910–2914.

18. Blake DR, Meigs JB, Muller DC, Najjar SS, Andres R, Nathan DM. Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on Aging. *Diabetes*. 2004;53: 2095–2100.

19. Tai ES, Goh SY, Lee JJ, Wong MS, Heng D, Hughes K, Chew SK, Cutter J, Chew W, Gu K, Chia KS, Tan CE. Lowering the criterion for impaired fasting glucose: impact on disease prevalence and associated risk of diabetes and ischemic heart disease. *Diabetes Care*. 2004;27: 1728–1734.

20. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care*. 2003;26:3160–3167.

21. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation*. 2005;112:2735–2752.

22. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation. *Diabet Med*. 2006;23:469–480.

23. Kim SH, Chunawala L, Linde R, Reaven GM. Comparison of the 1997 and 2003 American Diabetes Association classification of impaired fasting glucose: impact on prevalence of impaired fasting glucose, coronary heart disease risk factors, and coronary heart disease in a community-based medical practice. *J Am Coll Cardiol*. 2006;48:293–297.

24. Levitzky YS, Pencina MJ, D'Agostino RB, Meigs JB, Murabito JM, Vasan RS, Fox CS. Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study. *J Am Coll Cardiol*. 2008;51:264–270.

The effect of metabolic syndrome defined by various criteria on the development of ischemic stroke subtypes in a general Japanese population

Jun Hata [a,*], Yasufumi Doi [b], Toshiharu Ninomiya [a], Yumihiro Tanizaki [a], Koji Yonemoto [a], Masayo Fukuhara [a], Michiaki Kubo [a], Takanari Kitazono [b], Mitsuo Iida [b], Yutaka Kiyohara [a]

[a] *Department of Environmental Medicine, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka City 812-8582, Japan*
[b] *Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan*

ARTICLE INFO

ABSTRACT

Objective: We evaluated the impact of metabolic syndrome (MetS) defined by various criteria on the occurrence of ischemic stroke subtypes in a general Japanese population.
Methods: A total of 2452 residents of a Japanese community, Hisayama, aged 40 years or older, were followed up for 14 years. To define MetS, we used the original Japanese criteria, the modified Japanese criteria, the International Diabetes Federation (IDF) criteria, the original National Cholesterol Education Program's Adult Treatment Panel III (NCEP) criteria, and the modified NCEP criteria. We substituted a waist circumference of ≥ 90 cm in men and ≥ 80 cm in women for the values of ≥ 85 cm and ≥ 90 cm, respectively, in the modified Japanese criteria and for >102 cm and >88 cm, respectively, in the modified NCEP criteria.
Results: Only MetS defined by the modified Japanese criteria showed a significant association with the development of lacunar infarction, and its hazard ratios (HRs) for the development of atherothrombotic and cardioembolic infarction were significant and greater than those of MetS defined by the other criteria: adjusted HRs for lacunar, atherothrombotic and cardioembolic infarction were 1.94 (95% confidence interval (CI), 1.13–3.32; $P = 0.02$), 2.55 (95% CI, 1.25–5.18; $P = 0.01$) and 3.94 (95% CI, 1.89–8.22, $P < 0.001$), respectively, after adjustment for confounding factors.
Conclusion: Our findings suggest that MetS defined by the Japanese criteria with the modification of a waist circumference of ≥ 90 cm in men and ≥ 80 cm in women is a better predictor of each ischemic stroke subtype in the Japanese population.

1. Introduction

Stroke is a major cause of mortality and disability in Japan and other developed countries [1]. Ischemic stroke is the most common type of stroke and can be further divided into three subtypes based on the size and location of the affected arteries and their pathogenesis: lacunar infarction (LI), atherothrombotic infarction (ATI), and cardioembolic infarction (CEI) [2]. The Japanese population is characterized by a higher frequency of LI among the ischemic stroke subtypes [3]. The impact of risk factors on the occurrence of ischemic stroke differs among the subtypes [4].

Metabolic syndrome (MetS) is a constellation of abdominal obesity, dyslipidemia, impaired glucose tolerance and elevated blood pressure [5–7], and individuals with this condition have an elevated

risk of cardiovascular disease [8–10]. Several institutions have proposed various definitions of MetS. Among these, the MetS criteria of the National Cholesterol Education Program's Adult Treatment Panel III (NCEP) [5] and those of the International Diabetes Federation (IDF) [6] have been used most frequently in epidemiological studies. Recently, the Committee to Evaluate Diagnostic Standards for Metabolic Syndrome in Japan released a new definition of MetS for Japanese individuals (the Japanese criteria) [7]. Some epidemiological studies have reported that MetS is associated with high risk for the development of ischemic stroke [8–15]. However, to our knowledge, no epidemiological studies have prospectively evaluated the relationship between MetS and ischemic stroke subtype. Furthermore, it remains unclear which of these MetS criteria are better for predicting the risks of ischemic stroke and its subtypes.

The aim of this study was to evaluate the impact of MetS defined by the various criteria on the development of ischemic stroke and its subtypes in a prospective cohort study of a general Japanese population.

* Corresponding author. Tel.: +81 92 652 3080; fax: +81 92 652 3075.
E-mail address: junhata@envmed.med.kyushu-u.ac.jp (J. Hata).

2. Methods

2.1. Study population

The Hisayama Study is a population-based prospective cohort study of cerebro-cardiovascular diseases established in 1961 in the town of Hisayama, a suburb of the Fukuoka metropolitan area in Kyushu Island of Japan [16]. Based on data from the national census, the age and occupational distributions in Hisayama have been almost identical to those in Japan from 1961 to the present. In 1988, a screening examination for the present study was performed in the town. A detailed description of this examination was published previously [8,9]. Briefly, a total of 2736 residents aged 40 years or over (80.7% of the total population of this age range) participated in the examination. After the exclusion of 102 subjects who had a history of stroke or coronary heart disease, 121 subjects with no fasting blood samples and 61 subjects for whom waist circumference was not measured, the remaining 2452 subjects (1050 men and 1402 women) were enrolled in the present study.

This study was conducted with the approval of the Ethics Committee of the Faculty of Medicine, Kyushu University, and written informed consent was obtained from the study participants.

2.2. Risk factor measurements

At the baseline examination, each participant completed a self-administered questionnaire covering medical history, medical treatment for hypertension and diabetes, smoking habits, alcohol intake and leisure time activity. We asked whether subjects were receiving antihypertensive agents, oral hypoglycemic agents and/or insulin. We investigated the number of cigarettes smoked per day and the frequency of alcohol intake over the last year and the kinds and amounts of alcoholic beverages. Smoking habits were classified into currently habitual (≥1 cigarette per day) or not. Alcohol intake was classified into customary drinking of alcoholic beverage at least once a month or not. Subjects engaging in sports or other form of exertion ≥3 times a week during their leisure time made up the regular exercise group.

Blood pressure was measured three times on one occasion using a standard mercury sphygmomanometer in the sitting position after rest for at least five minutes. The mean of the three measurements was used for the analysis. Hypertension was defined as blood pressure ≥140/90 mmHg and/or current use of antihypertensive agents. The waist circumference was measured at the umbilical level in the standing position by a trained staff member. Electrocardiogram abnormalities were defined as left ventricular hypertrophy (Minnesota code, 3-1) and/or ST depression (Minnesota code, 4-1, 2 or 3).

At the baseline examination, blood samples were collected once from an antecubital vein after an overnight fast of at least 12 h for the determination of lipid and glucose levels. Serum total cholesterol, high-density lipoprotein cholesterol and triglyceride concentrations were determined enzymatically. Fasting plasma glucose levels were measured by the glucose oxidase method. Diabetes was defined as fasting plasma glucose ≥7.0 mmol/L and/or current use of insulin or oral medication for diabetes. Fresh voided urine samples were collected at the examination, and proteinuria was defined as a value of 1+ or more using a reagent strip.

2.3. Definitions of metabolic syndrome

Table 1 shows the various MetS criteria used in the present study. We used the original Japanese [7], the IDF [6] and the original NCEP [5] criteria and created two additional criteria sets, the modified Japanese and the modified NCEP criteria, which substituted the waist circumference of the IDF criteria for Asians, ≥90 cm

in men and ≥80 cm in women, for the original cutoff values in the definitions of abdominal obesity.

2.4. Follow-up survey

The subjects were followed up prospectively from December 1988 to November 2002 by repeated health examinations. Health status was checked yearly by mail or telephone for any subjects who did not undergo a regular examination or who had moved out of the town. We also established a daily monitoring system among the study team and local physicians or members of the Health and Welfare Office of the town. When a subject died, an autopsy was performed at the Departments of Pathology of Kyushu University. During the follow-up period, 479 subjects died, of whom 362 (75.6%) underwent autopsy. Only one subject was lost to follow-up.

2.5. Definition of ischemic stroke subtypes

The diagnosis of stroke was determined on the basis of clinical information including computed tomography (CT) and magnetic resonance imaging (MRI) of the brain, cerebral angiography, echocardiography, carotid ultrasonography and autopsy findings. In principle, ischemic stroke was defined as a sudden onset of nonconvulsive and focal neurological deficit due to brain ischemia persisting for over 24 h. Ischemic stroke was further divided into clinical subtypes: LI, ATI and CEI on the basis of the Classification of Cerebrovascular Disease III proposed by the National Institute of Neurological Disorders and Stroke of the United States [2].

A detailed method of classifying ischemic stroke has been published previously [4]. Briefly, LI was diagnosed as the presence of a relevant brainstem, basal ganglia, or subcortical hemispheric lesion with a diameter of <1.5 cm demonstrated on brain imaging or autopsy and no evidence of cerebral cortical or cerebellar impairment. ATI was diagnosed when the subjects had significant stenosis (>50%) or occlusion of a major cerebral artery with infarct size ≥1.5 cm on brain imaging or autopsy. The diagnosis of CEI was made on the basis of primary and secondary clinical features suggestive of CEI as reported by the Cerebral Embolism Task Force [17].

During the follow-up period, LI, ATI and CEI developed in 72, 40, and 33 subjects, respectively. Among them, all subjects underwent brain CT and/or MRI studies, and autopsies were performed on 70 subjects (71%) of 98 deceased cases until June 31, 2008. When sufficient clinical and morphologic information was obtained, a diagnosis of ischemic stroke subtype was defined as "definite". When the amount of either type of information was insufficient, the diagnostic level was defined as "probable". Diagnostic levels were defined as definite in 138 subjects and as probable in 7 subjects. In this study, we present the data regarding definite and probable stroke cases together, since these combined data were almost identical to that for definite cases only.

2.6. Statistical analysis

The SAS software version 9.2 was used to perform statistical analyses. Serum triglycerides were transformed into logarithms to improve skewed distributions. The prevalence of MetS in men and women were compared with the use of the χ^2 test. The hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using the Cox proportional hazards model. $P < 0.05$ was considered statistically significant.

3. Results

Table 2 shows the baseline characteristics of the study population by sex. The mean age was 58 years for men and 59 years for

Table 1
Metabolic syndrome criteria used in the present study.

	A. Original Japanese	B. Modified Japanese	C. IDF for Asians	D. Original NCEP	E. Modified NCEP
Definition of metabolic syndrome	(1)+ any two or more of the following	(1)+ any two or more of the following	(1)+ any two or more of the following	Three or more of the following	Three or more of the following
Components					
Abdominal obesity (waist circumference)	(1) ≥85 cm (men), ≥90 cm (women)	(1) ≥90 cm (men), ≥80 cm (women)	(1) ≥90 cm (men), ≥80 cm (women)	(1) >102 cm (men), >88 cm (women)	(1) ≥90 cm (men), ≥80 cm (women)
High blood pressure	(2) ≥130/85 mmHg and/or antihypertensive medication	(2) Same as A	(2) Same as A	(2) Same as A	(2) Same as A
Hyperglycemia (fasting plasma glucose)	(3) ≥6.1 mmol/L and/or antidiabetic medication	(3) Same as A	(3) ≥5.6 mmol/L and/or antidiabetic medication	(3) ≥6.1 mmol/L and/or antidiabetic medication	(3) Same as D
Dyslipidemia	(4) Triglycerides ≥1.7 mmol/L and/or HDLC <1.03 mmol/L	(4) Same as A	(4) Triglycerides ≥1.7 mmol/L	(4) Same as C	(4) Same as C
			(5) HDLC <1.03 mmol/L (men), <1.29 mmol/L (women)	(5) Same as C	(5) Same as C

IDF, International Diabetes Federation; NCEP, National Cholesterol Education Program; HDLC, high-density lipoprotein cholesterol.

women, and mean waist circumference was 82.0 cm and 81.1 cm, respectively. The frequencies of hypertension, diabetes, proteinuria, electrocardiogram abnormalities, smoking habits and alcohol intake and mean values of triglycerides were higher in men than in women, while mean values of total and high-density lipoprotein cholesterols were higher in women.

The prevalence of MetS was 13.8% (21.4% in men and 8.1% in women) as defined by the original Japanese criteria, 14.9% (10.0% in men and 18.5% in women) by the modified Japanese criteria, 25.5% (13.4% in men and 34.5% in women) by the IDF criteria, 19.9% (16.8% in men and 22.3% in women) by the original NCEP criteria and 27.2% (21.6% in men and 31.3% in women) by the modified NCEP criteria. The prevalence of MetS by the original Japanese criteria was significantly higher in men than in women ($P < 0.001$), while the prevalence of MetS defined by the other four criteria was higher in women than in men ($P < 0.001$ for all).

Table 3 presents the age-adjusted HRs for the development of ischemic stroke according to the status of each component of the five MetS criterias by sex. In men, abdominal obesity defined by waist circumference of ≥90 cm was significantly associated with the development of ischemic stroke, while abdominal obesity defined by various waist circumferences was not a significant risk factor for ischemic stroke in women. High blood pressure defined by blood pressure ≥130/85 mmHg and/or use of antihypertensive agents was a significant predictor of ischemic stroke

only in women. The definition of hyperglycemia in the Japanese and the NCEP criteria (≥6.1 mmol/L) was superior to that in the IDF criteria (≥5.6 mmol/L) for the prediction of the ischemic stroke in women. Hyperlipidemia of various definitions was not associated with the development of ischemic stroke in either sex.

Multivariate-adjusted HRs of the five MetS criteria for the development of ischemic stroke were estimated after adjustment for age, sex, serum cholesterol, proteinuria, electrocardiogram abnormalities, smoking habits, alcohol intake and regular exercise (Table 4). In men, MetS defined by the modified Japanese and the IDF criteria was an independent and significant risk factor for the occurrence of ischemic stroke, while MetS defined by all five criteria significantly increased the risk of ischemic stroke in women. In both sexes, HR was greater in the modified Japanese criteria than in the other criteria.

Finally, similar analyses were performed for each ischemic stroke subtype (Table 5). Only MetS defined by the modified Japanese criteria was significantly associated with the development of LI. MetS defined by the modified Japanese and the IDF criteria was a significant risk factor for ATI occurrence. MetS defined by the modified Japanese, the IDF or the modified NCEP criteria significantly increased the risk of CEI. For each ischemic stroke subtype, the HR was greater in the modified Japanese criteria than in the other criteria.

Table 2
Clinical characteristics of the study population by sex.

Variables	Men ($n = 1050$)	Women ($n = 1402$)
Age (years)	58 ± 11	59 ± 11
Waist circumference (cm)	82.0 ± 8.2	81.1 ± 10.1
Body mass index (kg/m²)	22.8 ± 2.9	23.0 ± 3.2
Systolic blood pressure (mmHg)	134 ± 20	132 ± 21
Diastolic blood pressure (mmHg)	81 ± 11	76 ± 11
Hypertension (%)	44.2	37.0
Fasting plasma glucose (mmol/L)	5.9 ± 1.3	5.7 ± 1.3
Diabetes mellitus (%)	11.3	7.3
Total cholesterol (mmol/L)	5.11 ± 1.07	5.56 ± 1.07
High-density lipoprotein cholesterol (mmol/L)	1.26 ± 0.31	1.34 ± 0.29
Triglycerides (mmol/L)	1.32 (0.41–4.22)	1.06 (0.41–2.72)
Proteinuria (%)	7.9	4.1
Electrocardiogram abnormalities (%)	19.0	13.1
Smoking habits (%)	50.4	6.7
Alcohol intake (%)	61.5	8.9
Regular exercise (%)	11.5	9.2

Values are means ± SD or percentage. Geometric means and 95% prediction intervals of triglycerides are shown due to the skewed distribution.

Table 3

Age-adjusted hazard ratios for the development of ischemic stroke according to status of each component of various metabolic syndrome criteria by sex.

Components	Status	Men			Women		
		Number of events/population at risk	Hazard ratio (95% confidence interval)	P	Number of events/population at risk	Hazard ratio (95% confidence interval)	P
Abdominal obesity (waist circumference)							
≥85 cm (men), ≥90 cm (women)[a]	No	35/621	1.00		60/1113	1.00	
	Yes	31/429	1.53 (0.94–2.50)	0.09	19/289	1.13 (0.68–1.90)	0.63
≥90 cm (men), ≥80 cm (women)[b,c,d]	No	48/873	1.00		30/601	1.00	
	Yes	18/177	2.39 (1.38–4.14)	0.002	49/801	1.16 (0.73–1.82)	0.53
>102 cm (men), >88 cm (women)[e]	No	66/1042	1.00		57/1069	1.00	
	Yes	0/8	0.00	0.99	22/333	1.16 (0.71–1.90)	0.55
High blood pressure							
≥130/85 mmHg and/or use of antihypertensive agents [a,b,c,d,e]	No	21/420	1.00		16/678	1.00	
	Yes	45/630	1.25 (0.74–2.12)	0.40	63/724	2.36 (1.33–4.17)	0.003
Hyperglycemia (fasting plasma glucose)							
≥6.1 mmol/L and/or use of antidiabetic medication[a,b,d,e]	No	43/764	1.00		52/1151	1.00	
	Yes	23/286	1.34 (0.81–2.23)	0.26	27/251	2.05 (1.28–3.26)	0.003
≥5.6 mmol/L and/or use of antidiabetic medication[c]	No	28/448	1.00		31/766	1.00	
	Yes	38/602	0.95 (0.59–1.56)	0.85	48/636	1.60 (1.02–2.52)	0.04
Hyperlipidemia							
Triglycerides ≥1.7 mmol/L and/or HDLC <1.03 mmol/L[a,b]	No	45/625	1.00		52/1072	1.00	
	Yes	21/425	0.80 (0.48–1.35)	0.40	27/330	1.41 (0.88–2.24)	0.15
Triglycerides ≥1.7 mmol/L[c,d,e]	No	51/742	1.00		58/1172	1.00	
	Yes	15/308	0.87 (0.49–1.56)	0.65	21/230	1.56 (0.94–2.57)	0.08
HDLC <1.03 mmol/L men), <1.29 mmol/L women)[c,d,e]	No	55/812	1.00		37/746	1.00	
	Yes	11/238	0.70 (0.37–1.33)	0.28	42/656	1.19 (0.76–1.85)	0.44

HDLC, High-density lipoprotein cholesterol.

[a] Original Japanese criteria.
[b] Modified Japanese criteria.
[c] International Diabetes Federation criteria for Asians.
[d] Modified NCEP criteria.
[e] Original National Cholesterol Education Program (NCEP) criteria.

Table 4

Multivariate-adjusted hazard ratios for the development of ischemic stroke according to MetS statuses by various definitions by sex.

Criteria	Men			Women		
	Number of events/population at risk	Hazard ratio (95% confidence interval)	P	Number of events/population at risk	Hazard ratio (95% confidence interval)	P
Original Japanese						
MetS(−)	48/825	1.00		65/1289	1.00	
MetS(+)	18/225	1.32 (0.76–2.30)	0.33	14/113	2.09 (1.17–3.75)	0.01
Modified Japanese						
MetS(−)	51/945	1.00		48/1142	1.00	
MetS(+)	15/105	3.07 (1.68–5.61)	<0.001	31/260	2.21 (1.39–3.51)	<0.001
IDF						
MetS(−)	50/909	1.00		38/918	1.00	
MetS(+)	16/141	2.66 (1.47–4.81)	0.001	41/484	1.74 (1.11–2.73)	0.02
Original NCEP						
MetS(−)	54/874	1.00		49/1090	1.00	
MetS(+)	12/176	1.10 (0.58–2.07)	0.77	30/312	1.73 (1.09–2.76)	0.02
Modified NCEP						
MetS(−)	46/823	1.00		39/963	1.00	
MetS(+)	20/227	1.59 (0.93–2.74)	0.09	40/439	1.73 (1.10–2.71)	0.02

Adjusted for age, total cholesterol, proteinuria, electrocardiogram abnormalities, smoking habits, alcohol intake and regular exercise. MetS, Metabolic syndrome; IDF, International Diabetes Federation; NCEP, National Cholesterol Education Program.

4. Discussion

In a long-term prospective study of a general Japanese population, we demonstrated that MetS was an independent and significant risk factor for all of ischemic stroke subtypes when the modified Japanese criteria, in which a waist circumference of ≥90 cm in men and ≥80 cm in women was substituted for the original cutoff values, was used.

Several prospective studies [10–15] including ours [8], have investigated significant associations between MetS defined by the NCEP criteria or their modification and the risk of ischemic stroke. In these studies, however, ischemic stroke was not classified into clinical subtypes. Only a few studies have reported the relationship between MetS and ischemic stroke subtypes. In a hospital-based case–control study of elderly Greek subjects, the prevalence of MetS was higher in the non-embolic stroke group including LI and ATI than in the control group [18]. A case–control study for Japanese ischemic stroke patients [19] demonstrated that MetS was significantly related to ATI but not to LI and CEI. Another clinical study in Japan [20] revealed that the prevalence of MetS defined by the original Japanese criteria was highest among patients with CEI followed by those with LI. To our knowledge, the present study is the first population-based prospective cohort study to investigate the association between MetS and the development of each ischemic stroke subtype.

Among the several MetS criteria, the cutoff values of waist circumference to define abdominal obesity are largely different. Because the cutoff values of waist circumference in the original NCEP criteria (>102 cm in men and >88 cm in women) were created for American subjects [5], these values seem to be unsuitable for the Japanese population. The original Japanese criteria used the cutoff values of ≥85 cm in men and ≥90 cm in women based on correlations with visceral fat mass [7]. However, the IDF has claimed that using these values produces "odd results" in relation to cardiovascular risk and recommends the use of cutoff values of ≥90 cm in men and ≥80 cm in women for Asian populations including Japanese [6]. In our previous study, we compared the ability to predict cardiovascular disease at each published cutoff level of waist circumference among the MetS criteria and demonstrated that the optimal cutoff point of waist circumference was 90 cm in men and 80 cm in women [9]. In the present study, we observed a similar result for the risk of ischemic stroke in men (Table 3).

Therefore, we created the modified Japanese and the modified NCEP criteria, which substitute waist circumference cutoff values of ≥90 cm in men and ≥80 cm in women for the original values. Among these five criteria, we found that the modified Japanese criteria were the best at predicting the risk of ischemic stroke and its subtypes. These findings are concordant with those of our previous study [9], in which MetS defined by the modified Japanese criteria was a better predictor for the development of cardiovascular disease.

In this study, the risks of ischemic stroke and all subtypes were higher for the modified Japanese MetS criteria than for the IDF or the modified NCEP criteria despite the identical cutoff values of waist circumference. One reason for this is the difference in the definition of hyperglycemia: the definition of hyperglycemia in the modified Japanese criteria (≥6.1 mmol/L) was superior to that in the IDF criteria (≥5.6 mmol/L) for the prediction of ischemic stroke in our subjects (Table 3). Another reason seems to be that abdominal obesity is an essential component for the modified Japanese criteria, but not for the NCEP criteria. These findings support the opinion that abdominal obesity should be an essential component for the diagnosis of MetS though there has been controversy over the necessity of abdominal obesity.

Our study demonstrated that MetS defined by the modified Japanese criteria appears to be a significant risk factor for the development of LI. Very few studies have examined the relationship between MetS and LI. A cross-sectional study recently demonstrated a significant association between MetS and silent LI [21]. LI develops due mainly to arteriolosclerosis such as lipohyalinosis, fibrinoid necrosis or microatheroma in penetrating arteries of the brain [22]. Some disorders in secretion of adipocytokines have been observed in the MetS status. For example, it was reported that plasma concentrations of adiponectin decreased in subjects with abdominal obesity [23], and lower adiponection levels were associated with impaired endothelial function [24]. It has also been demonstrated that the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) increased in subjects with abdominal obesity [25], and overexpression of PAI-1 was associated with subendocardial myocardial infarction as a result of perivascular fibrosis and thrombosis in penetrating coronary arteries in PAI-1 transgenic mice [26]. It is reasonably considered that similar arteriosclerotic lesions may also occur in penetrating brain arteries. Therefore, adipocytokine disorders may be related to endothelial

Table 5
Multivariate-adjusted hazard ratios for the development of ischemic stroke subtypes according to MetS status by various definitions.

Criteria	Lacunar infarction			Atherothrombotic infarction			Cardioembolic infarction		
	Number of events/population at risk	Hazard ratio (95% confidence interval)	P	Number of events/population at risk	Hazard ratio (95% confidence interval)	P	Number of events/population at risk	Hazard ratio (95% confidence interval)	P
Original Japanese									
MetS(−)	57/2114	1.00		31/2114	1.00		25/2114	1.00	
MetS(+)	15/338	1.50 (0.82–2.72)	0.19	9/338	1.61 (0.76–3.43)	0.22	8/338	1.96 (0.87–4.45)	0.11
Modified Japanese									
MetS(−)	51/2,087	1.00		28/2087	1.00		20/2087	1.00	
MetS(+)	21/365	1.94 (1.13–3.32)	0.02	12/365	2.55 (1.25–5.18)	0.01	13/365	3.94 (1.89–8.22)	<0.001
IDF									
MetS(−)	44/1,827	1.00		25/1827	1.00		19/1827	1.00	
MetS(+)	28/625	1.65 (0.98–2.78)	0.06	15/625	2.15 (1.06–4.34)	0.03	14/625	2.69 (1.27–5.68)	0.01
Original NCEP									
MetS(−)	50/1964	1.00		29/1964	1.00		24/1964	1.00	
MetS(+)	22/488	1.48 (0.88–2.47)	0.14	11/488	1.37 (0.67–2.79)	0.38	9/488	1.47 (0.67–3.21)	0.34
Modified NCEP									
MetS(−)	44/1,786	1.00		23/1786	1.00		18/1786	1.00	
MetS(+)	28/666	1.35 (0.83–2.22)	0.23	17/666	1.90 (0.99–3.63)	0.05	15/666	2.20 (1.08–4.45)	0.03

Adjusted for age, total cholesterol, proteinuria, electrocardiogram abnormalities, smoking habits, alcohol intake and regular exercise. MetS, Metabolic syndrome; IDF, International Diabetes Federation; NCEP, National Cholesterol Education Program.

dysfunction and induce arteriolosclerotic lesions in the brain leading to the development of LI.

In our subjects, MetS defined by the modified Japanese or IDF criteria was also clearly associated with the occurrence of ATI. ATI is caused by atherosclerosis in extracranial or intracranial arteries. There have been several other studies demonstrating associations between MetS and atherosclerotic lesions in extracranial or intracranial arteries [27,28].

In this study, MetS defined by the modified Japanese, IDF or modified NCEP criteria was associated with the development of CEI. CEI occurs due to thromboembolism from the heart to the arteries of the brain as a result of cardiac diseases such as atrial fibrillation, valvular heart diseases and myocardial infarction [17]. It was recently shown in a cohort study that MetS was a significant risk factor for the development of atrial fibrillation [29], which is the most common embolic source of CEI. In our study, the prevalence of atrial fibrillation at baseline was significantly higher in the subjects with CEI than in those without CEI (21.2% vs. 0.9%, $P < 0.001$). Consequently, it is considered that atrial fibrillation occurs on the pathway between MetS and CEI.

The strengths of our study include accurate measurement of MetS components including waist circumference at baseline, longitudinal population-based study design, long duration of follow-up, perfect follow-up of subjects and accuracy for diagnosis of stroke including ischemic stroke subtypes. One limitation of our study is that the diagnosis of MetS and other risk factors was based on a single measurement at baseline, as has been the case in other epidemiological studies. During the follow-up, risk factor levels could be changed due to modifications in lifestyle or medication; hence, misclassification of MetS is possible. This would weaken the association found in this study, biasing the results toward the null hypothesis. Therefore, the true association may be stronger than that shown in our study.

In conclusion, we have shown that MetS defined by the modified Japanese criteria is an independent and significant risk factor for the development of all ischemic stroke subtypes. In these criteria, the impact of MetS on the occurrence of CEI was largest, followed by those of ATI and LI. Because the prevalence of metabolic disorders has shown a steep increase during the past several decades in the overall Japanese population [3], our findings indicate that correction of MetS is important for prevention of all ischemic stroke subtypes in Japan.

Conflict of interest

No authors have any conflict of interest.

Acknowledgements

References

[1] Sudlow CLM, Warlow CP. Comparable studies of the incidence of stroke and its pathological types: results from an international collaboration. Stroke 1997;28:491–9.

[2] Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke 1990;21:637–76.

[3] Kubo M, Hata J, Doi Y, et al. Secular trends in the incidence of and risk factors for ischemic stroke and its subtypes in Japanese population. Circulation 2008;118:2672–8.

[4] Tanizaki Y, Kiyohara Y, Kato I, et al. Incidence and risk factors for subtypes of cerebral infarction in a general population: the Hisayama Study. Stroke 2000;31:2616–22.

[5] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97.

[6] Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome: a new world-wide definition: a consensus statement from the International Diabetes Federation. Diabet Med 2006;23:469–80.

[7] Committee to Evaluate Diagnostic Standards for Metabolic Syndrome. Definition and the diagnostic standard for metabolic syndrome. Nippon Naika Gakkai Zasshi 2005;94:794–809 [in Japanese].

[8] Ninomiya T, Kubo M, Doi Y, et al. Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population: the Hisayama Study. Stroke 2007;38:2063–9.

[9] Doi Y, Ninomiya T, Hata J, et al. Proposed criteria for metabolic syndrome in Japanese based on prospective evidence: the Hisayama Study. Stroke 2009;40:1187–94.

[10] McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care 2005;28:385–90.

[11] Koren-Morag N, Goldbourt U, Tanne D. Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic cardiovascular disease. Stroke 2005;36:1366–71.

[12] Najarian RM, Sullivan LM, Kannel WB, et al. Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study. Arch Intern Med 2006;166:106–11.

[13] Chen HJ, Bai CH, Yeh WT, et al. Influence of metabolic syndrome and general obesity on the risk of ischemic stroke. Stroke 2006;37: 1060–4.

[14] Kurl S, Laukkanen JA, Niskanen L, et al. Metabolic syndrome and the risk of stroke in middle-aged men. Stroke 2006;37:806–11.

[15] Boden-Albala B, Sacco RL, Lee HS, et al. Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study. Stroke 2008;39:30–5.

[16] Katsuki S. Epidemiological and clinicopathological study on cerebrovascular disease in Japan. Prog Brain Res 1966;21:64–89.

[17] Cerebral Embolism Task Force. Cardiogenic brain embolism: the second report of the Cerebral Embolism Task Force. Arch Neurol 1989;46:727–43.

[18] Milionis HJ, Kostapanos MS, Liberopoulos EN, et al. Different definitions of the metabolic syndrome and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects. Int J Clin Pract 2007;61:545–51.

[19] Kawamoto R, Tomita H, Oka Y, et al. Metabolic syndrome as a predictor of ischemic stroke in elderly persons. Intern Med 2005;44:922–7.

[20] Yokokawa H, Goto A, Terui K, et al. Prevalence of metabolic syndrome and serum marker levels in patients with four subtypes of cerebral infarction in Japan. J Clin Neurosci 2008;15:769–73.

[21] Park K, Yasuda N, Toyonaga S, et al. Significant associations of metabolic syndrome and its components with silent lacunar infarction in middle aged subjects. J Neurol Neurosurg Psychiatry 2008;79:719–21.

[22] Fisher CM. Lacunar strokes and infarcts: a review. Neurology 1982;32:871–6.

[23] Ryo M, Nakamura T, Kihara S, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004;68:975–81.

[24] Matsuzawa Y. Adiponectin: identification, physiology and clinical relevance in metabolic and vascular disease. Atherosclerosis Suppl 2005;6:7–14.

[25] Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAI-I in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996;2:800–3.

[26] Eren M, Painter CA, Atkinson JB, et al. Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 2002;106:491–6.

[27] Bonora E, Kiechl S, Willeit J, et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck Study. Diabetes Care 2003;26:1251–7.

[28] Bang OY, Kim JW, Lee JH, et al. Association of the metabolic syndrome with intracranial atherosclerotic stroke. Neurology 2005;65:296–8.

[29] Watanabe H, Tanabe N, Watanabe T, et al. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata Preventive Medicine Study. Circulation 2008;117:1255–60.

Circulating resistin is increased with decreasing renal function in a general Japanese population: the Hisayama Study

Ryoichi Kawamura[1,2], Yasufumi Doi[1,3], Haruhiko Osawa[2], Toshiharu Ninomiya[1,3], Jun Hata[1,3], Koji Yonemoto[1,3], Yumihiro Tanizaki[1,3], Mitsuo Iida[3], Hideichi Makino[2] and Yutaka Kiyohara[1]

[1]Department of Environmental Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, [2]Department of Molecular and Genetic Medicine, Ehime University Graduate School of Medicine, Ehime, Japan and [3]Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Correspondence and offprint requests to: Yutaka Kiyohara; E-mail: kiyohara@envmed.med.kyushu-u.ac.jp

Abstract

Background. The purpose of this study is to investigate the relationship between serum resistin levels and chronic kidney disease (CKD).

Methods. A total of 3192 community-dwelling subjects (1377 men, 1815 women), aged ≥40 years and without renal failure, were divided into four groups according to quartiles of serum resistin concentrations: ≤7.1, 7.2–9.9, 10.0–14.7 and ≥14.8 ng/mL. The associations of resistin levels with renal function status were examined cross-sectionally. The estimated glomerular filtration rate (eGFR) was calculated using the equation from the Modification of Diet in Renal Disease Study, and CKD was defined as an eGFR of <60 mL/min/1.73 m^2.

Results. The age- and sex-adjusted mean values of eGFR decreased significantly with elevating quartiles of resistin (P for trend <0.001). The age- and sex-adjusted odds ratios (ORs) for the presence of CKD increased progressively with higher quartiles of resistin. This trend remained robust even after controlling for age, sex, body mass index, diabetes, homeostasis model assessment of insulin resistance (HOMA-IR), high-sensitivity C-reactive protein (hs-CRP), triglycerides, high-density lipoprotein and total cholesterol, hypertension, current smoking, current drinking, and regular exercise [second quartile: OR 1.44, 95% confidence interval (CI) 1.05–1.99; third quartile: OR 2.15, 95% CI 1.58–2.92; fourth quartile: OR 2.32, 95% CI 1.71–3.16; P for trend <0.001]. In stratified analyses, high resistin level (≥7.2 ng/mL) was a significant relevant factor in CKD, independent of HOMA-IR or hs-CRP level.

Conclusion. Our findings suggest that elevated resistin level is significantly associated with the likelihood of CKD in the general Japanese population.

Keywords: chronic kidney disease; cross-sectional study; epidemiology; resistin

Introduction

Chronic kidney disease (CKD) is a worldwide public health concern and a major risk factor for end-stage renal disease, cardiovascular disease and premature death [1]. Identifying and treating risk factors for mild CKD may be the best approach to prevent and delay advanced outcomes [1]. Several epidemiological studies associated age, high blood pressure, diabetes, proteinuria, dyslipidaemia and smoking with the subsequent decline in estimated glomerular filtration rate (eGFR) [2,3]. It was also reported that insulin resistance and inflammation were emerging risk factors for the occurrence of CKD [4,5]. However, regardless of the treatment and prevention of these factors, patients with renal failure are increasing in number [6], suggesting the presence of other risk factors.

Resistin belongs to a family of cysteine-rich secretory proteins called resistin-like molecules [7]. In rodents, resistin is derived almost exclusively from fat tissue, and its serum levels are elevated in animal models of obesity and insulin resistance [8]. In humans, on the other hand, resistin is highly expressed in monocytes and macrophages [9]; thus, its pathophysiological role may differ between species. *In vitro*, resistin activated human endothelial cells, leading to increased expression of adhesion molecules, and induced human aortic muscle cell proliferation [10]. Furthermore, some clinical and epidemiological studies revealed positive correlations between plasma resistin levels and pro-inflammatory cytokines [11,12]. A few recent clinical studies also showed an inverse correlation between resistin level and eGFR in CKD patients [13–15]. To date, however, there have been no investigations into the link between serum resistin levels and CKD in large general populations excluding patients with renal failure. The aim of the present study is to examine the relationship between serum resistin levels and CKD in a cross-sectional study of a general Japanese population.

Table 1. Age- and sex-adjusted mean values or frequencies of risk factors according to quartiles of serum resistin concentrations

Variable	Serum resistin levels (ng/mL)				P-value for trend
	1.5–7.1 (n = 788)	7.2–9.9 (n = 803)	10.0–14.7 (n = 805)	14.8–90.2 (n = 796)	
Age (years)	59 ± 11	61 ± 12	62 ± 13	64 ± 13	<0.001
Men (%)	38.1	40.4	44.6	49.5	<0.001
BMI (kg/m^2)	23.0 ± 3.4	23.1 ± 3.4	23.0 ± 3.4	23.2 ± 3.4	0.50
Serum creatinine (μmol/L)	59 ± 15	62 ± 15	64 ± 15	65 ± 15	<0.001
Fasting plasma glucose (mmol/L)	6.1 ± 1.3	6.1 ± 1.3	6.0 ± 1.3	6.1 ± 1.3	0.70
Fasting insulin (pmol/L)	44.6 (13.8–144.5)	46.6 (14.5–150.0)	46.3 (14.4–148.7)	49.5 (15.3–160.5)	0.001
Diabetes (%)	16.5	16.8	18.0	18.9	0.45
HOMA-IR	1.66 (0.44–6.29)	1.72 (0.46–6.48)	1.71 (0.45–6.42)	1.83 (0.48–6.94)	0.007
Hs-CRP (mg/L)	0.44 (0.04–4.53)	0.51 (0.05–5.28)	0.54 (0.05–5.49)	0.66 (0.06–6.88)	<0.001
Triglycerides (mmol/L)	1.12 (0.39–3.18)	1.16 (0.41–3.29)	1.14 (0.40–3.23)	1.17 (0.41–3.35)	0.13
HDL-cholesterol (mmol/L)	1.70 ± 0.40	1.61 ± 0.40	1.62 ± 0.40	1.55 ± 0.40	<0.001
Total cholesterol (mmol/L)	5.30 ± 0.90	5.27 ± 0.89	5.31 ± 0.89	5.23 ± 0.90	0.15
Systolic blood pressure (mmHg)	132 ± 20	132 ± 20	132 ± 20	132 ± 20	0.96
Diastolic blood pressure (mmHg)	79 ± 12	79 ± 12	78 ± 12	78 ± 12	0.66
Hypertension (%)	45.0	42.9	43.2	46.3	0.98
Current smoking (%)	20.7	21.5	21.9	22.8	0.29
Current drinking (%)	48.8	44.4	43.4	38.3	<0.001
Regular exercise (%)	11.1	10.4	9.8	8.7	0.04

Values are given as means ± SD or frequencies. Age and percentage of men are not adjusted. Fasting insulin, HOMA-IR, hs-CRP and triglycerides are shown by geometric means and 95% CIs due to the skewed distribution.BMI, body mass index; HOMA-IR, homeostasis model assessment of insulin resistance; hs-CRP, high-sensitivity C-reactive protein; HDL, high-density lipoprotein.

Materials and methods

Study population

A population-based prospective study of cardiovascular disease has been under way since 1961 in the town of Hisayama, a suburb of Fukuoka City in southern Japan. As part of this study, in 2002, we conducted a cross-sectional examination among residents of the town. A detailed description of this survey was published previously [16]. Briefly, of all residents aged 40 years or over, 3328 underwent the examination (participation rate, 77.6%). After excluding 30 subjects who did not consent to participate in the study, 13 subjects with renal failure (eGFR <15 mL/min/1.73 m^2 or treated by dialysis), 82 subjects who had already eaten breakfast on the day serum samples were to be taken and 11 subjects without serum samples for resistin measurement, the remaining 3192 subjects (1377 men, 1815 women) were enrolled in this study.

This study was conducted with the approval of the Ethics Committee of the Faculty of Medicine, Kyushu University. Written informed consent was obtained from all participants.

Clinical evaluation and laboratory measurements

At the screening examination, blood samples were collected from an antecubital vein between 8:00 and 10:30 a.m. after at least a 12-h overnight fast. A portion of each serum specimen was stored at −80°C for 5 years, until 2007, when it was used for the measurement of resistin concentrations by a human resistin enzyme-linked immunosorbent assay kit supplied by R&D Systems (Minneapolis, MN) following the manufacturer's protocol. Linearity was maintained <0.16 ng/mL, and both intra- and inter-assay coefficient variations were comparable to those specified by the manufacturer (2.6–10.5%). Using fresh blood samples, serum creatinine was measured by the enzymatic method. Levels of triglycerides, high-density lipoprotein (HDL) and total cholesterol were determined enzymatically. Blood for the glucose assay was obtained by venipuncture into tubes containing sodium fluoride, and plasma glucose concentrations were determined by the glucose oxidase method. Subjects were considered to have diabetes mellitus if they had a fasting plasma glucose level of ≥7.0 mmol/L, had a 2-h post-load glucose level of ≥11.1 mmol/L or were taking antidiabetic medications. Serum insulin values were measured by a chemiluminescent enzyme immunoassay. The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated with the formula fasting plasma glucose (mmol/L) × fasting serum insulin (μU/mL) / 22.5 [17], and subjects in the top quartile of HOMA-IR distribution were defined

as having insulin resistance [18]. High-sensitivity C-reactive protein (hs-CRP) levels were quantified using a modification of the Behring latex-enhanced CRP assay on a Behring nephelometer BN-100 (Behring Diagnostics, Westwood, MA). High CRP values were defined as ≥1.0 mg/L, according to our previous report [19].

Blood pressure was obtained three times using an automated sphygmomanometer (BP-203RV III; Colin, Tokyo, Japan) with the subjects in a sitting position; the average of the three measurements was used in the present analysis. Hypertension was defined as systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg or current treatment with antihypertensive agents. Height and weight were measured with the subject wearing light clothes without shoes, and body mass index [BMI (kg/m^2)] was calculated.

Each participant completed a self-administered questionnaire covering medical history, smoking habit, alcohol intake and exercise. The questionnaire was checked by trained interviewers at the screening. Smoking habit and alcohol intake were classified as either current habitual use or not. Those subjects who engaged in sports or other forms of exertion ≥3 times a week during their leisure time made up a regular exercise group.

Definition of CKD

GFR was estimated by using the following modified equation of the Modification of Diet in Renal Disease (MDRD) Study for Japanese [20]: eGFR (mL/min/1.73 m^2) = 175 × [serum creatinine (mg/dL)]$^{-1.154}$ × [age (years)]$^{-0.203}$ × [0.741 (Japanese coefficient)] × (0.742 if female). Based on the National Kidney Foundation Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines [1], we divided kidney function levels into four categories according to eGFR: normal and CKD stage 1 (eGFR ≥90 mL/min/1.73 m^2), CKD stage 2 (eGFR 60–89 mL/min/1.73 m^2), CKD stage 3 (eGFR 30–59 mL/min/1.73 m^2) and CKD stage 4 (eGFR 15–29 mL/min/1.73 m^2). We also determined CKD as a dichotomized category when eGFR was <60 mL/min/1.73 m^2.

Statistical analysis

SAS software package version 8.2 (SAS Institute, Cary, NC) was used to perform all statistical analyses. Because the distributions of fasting insulin, HOMA-IR, hs-CRP and triglycerides were skewed, these variables were natural log-transformed for statistical analysis. The subjects were divided into quartiles of resistin concentrations: ≤7.1, 7.2–9.9, 10.0–14.7 and ≥14.8 ng/mL. The mean values of possible risk factors were adjusted for

Fig. 1. The age- and sex-adjusted mean values of estimated glomerular filtration rate (eGFR) according to quartiles of serum resistin concentrations (left panel), and the age- and sex-adjusted mean values of serum resistin levels according to eGFR (right panel). Values are given as means ± standard error. *P < 0.001 *vs* the first quartile, †P < 0.001 *vs* eGFR of ≥90 mL/min/1.73 m².

age and sex using the analysis of covariance and were compared among the resistin quartiles according to the linear regression model. Age- and sex-adjusted means of eGFR among the quartiles were determined by the same method. The frequencies of risk factors were adjusted for age and sex by the direct method using all subjects as a standard population and were tested for trends using logistic regression analysis. The age- and sex- or multivariate-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for CKD were also determined by logistic regression analysis.

Results

Table 1 shows the age- and sex-adjusted means or frequencies of potential risk factors according to the quartiles of serum resistin concentrations. The mean values of age, serum creatinine, fasting insulin, HOMA-IR and hs-CRP, as well as the percentage of men, increased with the quartiles of resistin values, while the mean HDL cholesterol concentration and the frequencies of alcohol intake and regular exercise were negatively correlated with the quartiles. The other variables were not significantly associated with the quartiles.

The left panel in Figure 1 shows the age- and sex-adjusted mean values of eGFR according to the quartiles of serum resistin values. The mean values of eGFR decreased signif-

icantly with the quartiles of resistin values (80.4, 76.7, 74.2 and 73.9 mL/min/1.73 m², respectively; P for trend <0.001). Meanwhile, the age- and sex-adjusted mean values of serum resistin according to eGFR are shown in the right panel in Figure 1. The age- and sex-adjusted geometric mean values of serum resistin increased significantly as eGFR decreased (9.5 ng/mL in the normal and CKD stage 1, 10.2 ng/mL in CKD stage 2, 11.8 ng/mL in CKD stage 3 and 21.1 ng/mL in CKD stage 4; P for trend <0.001): the differences were significant between normal and CKD stage 1 and CKD stages 2–4 (all P < 0.001).

Table 2 shows the age- and sex-adjusted or multivariate-adjusted ORs and 95% CIs for the presence of CKD according to the resistin quartiles. The age- and sex-adjusted OR for CKD significantly increased with elevating quartiles (P for trend <0.001); compared to the first quartile, OR was greater in the second to fourth quartiles. Such associations were substantially unchanged after adjustment for age, sex, BMI, diabetes, HOMA-IR, hs-CRP, triglycerides, HDL and total cholesterol, hypertension, current smoking, current drinking, and regular exercise (second quartile: OR 1.44, 95% CI 1.05–1.99; third quartile: OR 2.15, 95% CI 1.58–2.92; fourth quartile: OR 2.32, 95% CI 1.71–3.16).

Table 2. Age- and sex- or multivariate-adjusted ORs and their 95% CIs for the presence of chronic kidney disease according to quartiles of serum resistin concentrations

	Serum resistin levels (ng/mL)				
	1.5–7.1	7.2–9.9	10.0–14.7	14.8–90.2	P-value for trend
Subjects (n)	788	803	805	796	
CKD cases (n)	75	117	166	192	
Age- and sex-adjusted OR (95% CI)	1 (reference)	1.44 (1.06–1.98)	2.15 (1.59–2.90)	2.33 (1.73–3.14)	<0.001
Multivariate-adjusted OR (95% CI)	1 (reference)	1.44 (1.05–1.99)	2.15 (1.58–2.92)	2.32 (1.71–3.16)	<0.001

Multivariate adjustment was made for age, sex, body mass index, diabetes, homeostasis model assessment of insulin resistance, high-sensitivity C-reactive protein, triglycerides, high-density lipoprotein and total cholesterol, hypertension, current smoking, current drinking, and regular exercise.CKD, chronic kidney disease; OR, odds ratio; CI, confidence interval.

Table 3. Age- and sex- or multivariate-adjusted ORs and their 95% CIs for chronic kidney disease according to the presence or absence of high resistin levels and high HOMA-IR as well as high hs-CRP values

	Subjects, n	CKD cases, n	Age- and sex-adjusted OR (95% CI)	P-value	Multivariate-adjusted OR (95% CI)	P-value
HOMA-IR						
Low + low resistin	602	57	1 (reference)		1 (reference)	
Low + high resistin	1773	340	1.84 (1.35–2.49)	<0.001	1.85 (1.35–2.52)	<0.001
High + low resistin	178	17	1.00 (0.56–1.78)	0.99	0.93 (0.51–1.68)	0.80
High + high resistin	613	131	2.34 (1.66–3.29)	<0.001	2.14 (1.47–3.12)	<0.001
hs-CRP						
Low + low resistin	645	53	1 (reference)		1 (reference)	
Low + high resistin	1717	309	2.13 (1.56–2.91)	<0.001	2.12 (1.54–2.91)	<0.001
High + low resistin	143	22	1.69 (0.98–2.92)	0.06	1.62 (0.92–2.84)	0.09
High + high resistin	687	166	2.45 (1.74–3.45)	<0.001	2.46 (1.72–3.50)	<0.001

High resistin levels were defined as the second or higher quartiles of its values; low resistin levels were the first quartile of its values.HOMA-IR: 'high' indicates ≥75th percentile (HOMA-IR ≥2.6); 'low' <75th percentile.Hs-CRP: 'high' indicates ≥1.0 mg/L; 'low' <1.0 mg/L. Multivariate adjustment was made for age, sex, body mass index, diabetes, HOMA-IR, hs-CRP, triglycerides, high-density lipoprotein and total cholesterol, hypertension, current smoking, current drinking, and regular exercise, but each risk factor that had been used for categorization was excluded from the confounding factors.CKD, chronic kidney disease; HOMA-IR, homeostasis model assessment of insulin resistance; hs-CRP, high-sensitivity C-reactive protein; OR, odds ratio; CI, confidence interval.

Finally, we examined the combined as well as separate effects of resistin and HOMA-IR or hs-CRP levels on the presence of CKD (Table 3). When a high resistin level was in the second or higher quartile (≥7.2 ng/mL), the age- and sex-adjusted ORs of CKD were significantly higher in subjects with high resistin and low HOMA-IR (<75th percentile) and in subjects with high resistin and high HOMA-IR (≥75th percentile) compared to the reference group, who had low resistin and low HOMA-IR. Similarly, the age- and sex-adjusted risks of CKD were significantly higher in subjects with high resistin levels, independent of hs-CRP levels. These relationships remained robust even after adjusting for the confounding factors named above.

Discussion

Using the large cross-sectional data of a general Japanese population, we demonstrated that serum resistin levels were negatively associated with eGFR, and that the mean values of serum resistin increased even in CKD stage 2. Furthermore, the elevated levels of serum resistin were an independent relevant factor for CKD after controlling for age, sex, BMI, diabetes, HOMA-IR, hs-CRP, triglycerides, HDL and total cholesterol, hypertension, current smoking, current drinking, and regular exercise. In stratified analyses, high resistin levels were associated significantly with the likelihood of CKD in those with low HOMA-IR (<75th percentile) as well as in those with low hs-CRP levels (<1.0 mg/L). These findings suggest that the measurement of resistin values provides additional information on the risk factors for CKD.

In a few clinical studies of CKD patients, resistin levels have been shown to be inversely correlated with eGFR [13–15]. Although polypeptides that have molecular weights comparable to those of resistin are thought to be freely filtered at the normal glomerulus [21], subjects with advanced renal impairment might have serum resistin accumulations due to reduced renal clearance: that is, renal

dysfunction might cause elevated serum resistin levels. However, the present study showed that resistin levels were significantly raised even in subjects with CKD stage 2 (eGFR of 60–89 mL/min/1.73 m²), in which polypeptides would be filtered almost normally. In a clinical study of patients with immunoglobulin A glomerulonephritis, serum resistin levels were also significantly higher in subjects with mild renal dysfunction who had a mean GFR of 76 mL/min/1.73 m² than in those who had a mean GFR of 114 mL/min/1.73 m² [13]. These observations support the hypothesis that resistin potentially plays an important role in the development of CKD.

It has been assumed that the effect of resistin is mediated via insulin resistance or inflammation. In our study, serum resistin levels were positively associated with HOMA-IR, but the association between circulating resistin levels and the likelihood of CKD was independent of HOMA-IR, which is in accord with the results of other clinical studies [13,14,22]. Thus, insulin resistance may not be a major mediator of the association between resistin levels and the risk of CKD. Meanwhile, the present study also indicated that the association between resistin levels and the likelihood of CKD was unrelated to hs-CRP, though resistin levels were closely associated with those levels. Resistin directly stimulated the expression of pro-inflammatory cytokines such as tumour necrosis factor-α and interleukin-6 in human peripheral blood mononuclear cells [23], and increased the expression of vascular cell adhesion molecule-1 and intracellular adhesion molecule-1 genes in vascular endothelial cells [10]. Furthermore, a recent clinical study provided evidence that the association between plasma resistin levels and plasma monocyte chemoattractant protein-1 concentrations was independent of hs-CRP levels [24]. Since it has become apparent that CKD is a state of chronic glomerular inflammation [5], resistin may play an important role in potentiating inflammation in the kidney, irrespective of hs-CRP and other confounding factors.

There are a variety of methods for estimating GFR. Although inulin clearance is the gold standard among these

methods, it is difficult to perform in routine practice. During the past decade, a great deal of effort has been devoted to establishing an equation for estimating GFR. There is a debate about which equation is optimal for Japanese; the original MDRD Study equation is widely accepted by clinical practitioners, but it may be unsuitable for Asian populations [20]. When some existing equations, such as the original MDRD Study equations [25] or the Cockcroft–Gault formula [26], were used instead of the modified MDRD Study equation for Japanese in our subjects, we also found significant associations between elevated resistin levels and CKD (data not shown). These findings imply a robust association between serum resistin levels and CKD.

A limitation of our study should be discussed. Due to the study's cross-sectional design, we cannot exclude the possibility that hyperresistinaemia is a consequence of CKD, which is a condition of low urine excretion from serum. However, we found significantly increased resistin levels even when eGFR was 60–89 mL/min/1.73 m^2. Thus, we believe that elevated resistin levels are a potential risk factor for the development of CKD.

In conclusion, an elevated resistin level was a significant relevant factor for CKD in a general Japanese population after taking into account other risk factors, including HOMA-IR and hs-CRP. Because of the cross-sectional design of this study, it is still unclear whether or not hyperresistinaemia is a cause of CKD. Further prospective studies are needed to clarify the causative relationship between serum resistin concentrations and CKD.

References

1. National Kidney FoundationK/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 2002; 39: S1–S266
2. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the Atherosclerosis Risk in Communities Study. *Kidney Int* 2000; 58: 293–301
3. Fox CS, Larson MG, Leip EP *et al.* Predictors of new-onset kidney disease in a community-based population. *JAMA* 2004; 291: 844–850
4. Chen J, Muntner P, Hamm LL *et al.* Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. *J Am Soc Nephrol* 2003; 14: 469–477
5. Landray MJ, Wheeler DC, Lip GY *et al.* Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the Chronic Renal Impairment in Birmingham (CRIB) Study. *Am J Kidney Dis* 2004; 43: 244–253
6. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. *J Am Soc Nephrol* 2002; 13: S37–S40

7. Steppan CM, Lazar MA. The current biology of resistin. *J Intern Med* 2004; 255: 439–447
8. Steppan CM, Bailey ST, Bhat S *et al.* The hormone resistin links obesity to diabetes. *Nature* 2001; 409: 307–312
9. Patel L, Buckels AC, Kinghorn IJ *et al.* Resistin is expressed in human macrophages and directly regulated by PPARg activators. *Biochem Biophys Res Commun* 2003; 300: 472–476
10. Verma S, Li SH, Wang CH *et al.* Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. *Circulation* 2003; 108: 736–740
11. Kunnari A, Ukkola O, Päivänsalo M, Kesäniemi YA. High plasma resistin level is associated with enhanced highly sensitive C-reactive protein and leukocytes. *J Clin Endocrinol Metab* 2006; 91: 2755–2760
12. Shetty GK, Economides PA, Horton ES, Martzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. *Diabetes Care* 2004; 27: 2450–2457
13. Kielstein JT, Becker B, Graf S *et al.* Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. *Am J Kidney Dis* 2003; 42: 62–66
14. Axelsson J, Bergsten A, Qureshi AR *et al.* Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. *Kidney Int* 2006; 69: 596–604
15. Nusken KD, Kratzsch J, Wienholz V *et al.* Circulating resistin concentrations in children depend on renal function. *Nephrol Dial Transplant* 2006; 21: 107–112
16. Doi Y, Kubo M, Yonemoto K *et al.* Fasting plasma glucose cutoff for diagnosis of diabetes in a Japanese population. *J Clin Endocrinol Metab* 2008; 93: 3425–3429
17. Matthews DR, Hosker JP, Rudenski AS *et al.* Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985; 28: 412–419
18. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 1998; 15: 539–553
19. Arima H, Kubo M, Yonemoto K *et al.* High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama Study. *Arterioscler Thromb Vasc Biol* 2008; 28: 1385–1391
20. Imai E, Horio M, Nitta K *et al.* Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan. *Am J Kidney Dis* 2007; 50: 927–937
21. Kataoka H, Sharma K. Renal handling of adipokines. *Contrib Nephrol* 2006; 151: 91–105
22. Ellington AA, Malik AR, Klee GG *et al.* Association of plasma resistin with glomerular filtration rate and albuminuria in hypertensive adults. *Hypertension* 2007; 50: 708–714
23. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. *J Immunol* 2005; 174: 5789–5795
24. Aquilante CL, Kosmiski LA, Knutsen SD, Zineh I. Relationship between plasma resistin concentrations, inflammatory chemokines, and components of the metabolic syndrome in adults. *Metabolism* 2008; 57: 494–501
25. Levey AS, Bosch JP, Lewis JB *et al.* A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med* 1999; 130: 461–470
26. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976; 16: 31–41

Insulin resistance is associated with the pathology of Alzheimer disease

The Hisayama Study

T. Matsuzaki, MD
K. Sasaki, MD, PhD
Y. Tanizaki, MD, PhD
J. Hata, MD, PhD
K. Fujimi, MD, PhD
Y. Matsui, MD, PhD
A. Sekita, MD
S.O. Suzuki, MD, PhD
S. Kanba, MD, PhD
Y. Kiyohara, MD, PhD
T. Iwaki, MD, PhD

Address correspondence and reprint requests to Dr. Kensuke Sasaki, Department of Neuropathology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
ksasaki@np.med.kyushu-u.ac.jp

ABSTRACT

Objective: We examined the association between diabetes-related factors and pathology of Alzheimer disease (AD) to evaluate how diabetes affects the pathogenic process of AD.

Methods: This study included specimens from a series of 135 autopsies of residents of the town of Hisayama in Fukuoka prefecture (74 men and 61 women) performed between 1998 and 2003, who underwent a 75-g oral glucose tolerance test in clinical examinations in 1988. We measured diabetes-related factors including fasting glucose, 2-hour post-load plasma glucose, fasting insulin, and homeostasis model assessment of insulin resistance (HOMA-IR) in 1988. Neuritic plaques (NPs) were assessed according to the Consortium to Establish a Registry for Alzheimer's Disease guidelines and neurofibrillary tangles (NFTs) were assessed according to Braak stage. The associations between each factor and AD pathology were examined by analysis of covariance and logistic regression analyses.

Results: Higher levels of 2-hour post-load plasma glucose, fasting insulin, and HOMA-IR were associated with increased risk for NPs after adjustment for age, sex, systolic blood pressure, total cholesterol, body mass index, habitual smoking, regular exercise, and cerebrovascular disease. However, there were no relationships between diabetes-related factors and NFTs. Regarding the effects of APOE genotype on the risk of AD pathology, the coexistence of hyperglycemia and APOE ε4 increased the risk for NP formation. A similar enhancement was observed for hyperinsulinemia and high HOMA-IR.

Conclusion: The results of this study suggest that hyperinsulinemia and hyperglycemia caused by insulin resistance accelerate NP formation in combination with the effects of APOE ε4. *Neurology®* 2010;75:764-770

GLOSSARY

AD = Alzheimer disease; **BMI** = body mass index; **CERAD** = Consortium to Establish a Registry for Alzheimer's Disease; **CI** = confidence interval; **FPG** = fasting plasma glucose; **GSK3** = glycogen synthase kinase 3; **HOMA-IR** = homeostasis model assessment of insulin resistance; **IDE** = insulin-degrading enzyme; **NFT** = neurofibrillary tangle; **NP** = neuritic plaque; **OGTT** = oral glucose tolerance test; **OR** = odds ratio; **PG** = post-load plasma glucose.

The prevalence of diabetes is growing at epidemic proportions worldwide, and is becoming a major health problem. Several large longitudinal population-based studies have shown that the rate of cognitive decline is accelerated in elderly people with type 2 diabetes compared with the general population.[1-3] Similarly, other epidemiologic studies have revealed that diabetes increases the risk of dementia,[2,4-7] including Alzheimer disease (AD), which is the most common cause of dementia in late life.[2,4,5,8,9] Therefore, the effect of diabetes on cognitive function in the elderly has significant public health implications.

Several lines of evidence indicate a role of insulin and glucose metabolism on the risk of developing dementia, including AD.[10-14] Many mechanisms through which diabetes could increase the risk of dementia have been postulated, and include glucose toxicity, insulin resis-

tance, oxidative stress, advanced glycation end products, inflammatory cytokines, and microvascular and macrovascular disease.[15] However, the determinant pathway, which is more critical to AD pathogenesis, is less clear. Understanding the role of disease-related risk factors for AD pathogenesis may help to identify specific modifiable risk factors that could enable the prevention of AD.[16] Therefore, identifying the dominant pathway through which diabetes influences the pathogenic process of AD may have benefits for public health.

To clarify the relationship between diabetes and AD, we searched for evidence of AD-related pathologic risk by examining the associations between diabetes-related factors and typical AD-related pathologic outcomes, neuritic plaques (NPs) and neurofibrillary tangles (NFTs).

METHODS Subjects. Since 1961, we have been conducting a long-term prospective cohort study of cerebro-cardiovascular diseases in the town of Hisayama, a suburb of the city of Fukuoka in southern Japan. The design of the Hisayama Study has been described in detail elsewhere.[17-19] In the present study, we examined a series of autopsy samples of Hisayama residents from October 1, 1998, to March 31, 2003. During this period, 290 residents in Hisayama died and 214 were autopsied (autopsy rate: 73.8%). The clinical data for the present study were collected from a clinical examination performed in 1988, as described previously.[19] Briefly, of a total of 3,390 residents aged over 40 years included in this registry, 2,742 (participation rate, 80.9%) took part in a clinical examination in 1988. Of these, a 75-g oral glucose tolerance test (OGTT) was performed in 2,520 subjects. Of the 214 autopsy cases, we excluded 3 subjects whose brain specimens were inadequate for evaluation, and 76 subjects who did not complete the OGTT in 1988. Finally, 135 subjects who underwent both the OGTT and brain autopsy were included in the present study. None of the 135 subjects showed signs of dementia at the clinical examination in 1988. Careful surveillance of cognitive impairment was carried out through a daily monitoring system established by the study team, local practitioners, and the town government.[9,18]

Standard protocol approvals, registrations, and patient consents. The study was approved by the Ethics Committee of the Faculty of Medicine, Kyushu University, and was performed in accordance with the ethical standards described in the 5th revision of the Declaration of Helsinki, 2000. Written informed consent was obtained from all study subjects.

Risk factors. In the clinical examination performed in 1988, the 75-g OGTT was performed after at least a 12-hour overnight fast and the following 3 diabetes-related factors were determined: fasting plasma glucose (FPG), 2-hour post-load plasma glucose (2-hour PG), and fasting insulin. Glucose was determined by the glucose oxidase method and fasting insulin was determined by a radioimmunoassay. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated using the following equa-

tion: FPG (mmol/L) × fasting insulin (μU/mL)/22.48155.[20] Blood pressure was measured 3 times at the right upper arm using a mercury sphygmomanometer after at least 5 minutes of rest in a sitting position; the mean of the 3 measurements was used in the analysis. Total cholesterol levels were determined enzymatically. Height and weight were measured in light clothes without shoes, and body mass index (BMI; weight/height squared, kg/m²) was calculated. Information on exercise and smoking habits was obtained via a standard questionnaire, and these factors were classified as being habitual or not. Regular exercise means engaging in sports or other forms of exertion regularly more than 3 times per week during leisure time. APOE genotyping was determined by direct sequencing at Takara Bio Inc., Japan. No homozygous $\epsilon 4$ genotype was found among these participants, and those who carried 1 copy of the $\epsilon 4$ allele were categorized as APOE $\epsilon 4$ carriers.

Assessment of neuropathologic changes. The assessment of AD pathology was conducted according to the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) guidelines and Braak stage established by Braak and Braak.[21-23] Brains were fixed in 10% buffered formalin for at least 2 weeks. Brain specimens in each case included the middle frontal gyrus, superior and middle temporal gyri, inferior parietal lobule, anterior cingulated gyrus, amygdala, hippocampus with entorhinal and transentorhinal cortex (at the level of the lateral geniculate body), calcarine cortex, basal ganglia including the nucleus basalis of Meynert, thalamus, substantia nigra, locus ceruleus, and dorsal vagal nucleus. Sections were embedded in paraffin and were routinely stained using hematoxylin-eosin, Klüver-Barrera, and a modified Bielschowsky method. Specimens from each subject were immunostained with antibodies against phosphorylated tau (AT8, mouse monoclonal, 1:500; Innogenetics, Belgium). Immunolabeling was detected using a standard indirect immunoperoxidase method and visualized using diaminobenzidine (Dojindo, Japan) as a chromogen. The frequency of NPs defined by the CERAD criteria were semiquantitatively categorized into the following 4 groups: none (score 0), sparse (score 1), moderate (score 2), and frequent (score 3). The extent of NFTs according to Braak stage was semiquantitatively classified into the following 4 groups: stage 0, stage I to II, stage III to IV, and stage V to VI. For the pathologic assessment of cerebrovascular diseases, any types of cerebral infarctions and hemorrhages were registered according to gross examination and microscopic assessment, regardless of clinical features. This factor was classified as being present or not.

Statistical analyses. Statistical analyses were conducted using SAS software version 9 (SAS Institute, Cary, NC). Mean or geometric mean values of the diabetes-related factors among the groups of NPs or NFTs were calculated and compared by analysis of covariance, with adjustment for age at clinical examination and sex. We used logistic regression analysis to determine relationships between the risk factors (diabetes-related factors, APOE genotype, and their interaction) and pathologic outcome (presence or absence of NPs and NFTs) and are expressed as odds ratios (OR) and 95% confidence intervals (CI). Continuous variables (FPG, fasting insulin, and HOMA-IR) were divided into 3 groups to compare the risk of NPs among tertiles. Missing values (1 for fasting insulin, 1 for HOMA-IR, 6 for APOE $\epsilon 4$ carrier, and 1 for the grading of Braak stage) were excluded from the analysis. Age at clinical examination was used for adjustment in the present study; adjustment for age at death resulted in equivalent statistical outcomes. Significance was de-

−214−

fined as $p < 0.05$, and marginal significance was defined as $0.05 \leq p < 0.10$ in statistical analysis.

RESULTS The characteristics of the study subjects at clinical examination in 1988 (n = 135) are described in table 1. Mean ± SD age at clinical examination was 67.0 ± 9.5 and mean ± SD age at death was 79.5 ± 9.3 years, and 54.8% (n = 74) of the subjects were male. Overall, 19.4% (n = 25) of subjects were carrying *APOE* ϵ4. There was no selection bias regardless of autopsy, according to a comparison

of demographic characteristics between our study subjects and those who did not undergo autopsy (data not shown). Out of the 135 subjects, 15.6% (n = 21) developed Alzheimer-type dementia. Based on the assessment of AD pathology, the frequencies of NPs were categorized into the following 4 groups by CERAD criteria: 34.8% (n = 47) for none (score 0), 17.0% (n = 23) for sparse (score 1), 14.1% (n = 19) for moderate (score 2), and 34.1% (n = 46) for frequent (score 3). The frequencies of NFTs were classified into the following 4 groups by Braak stage: 14.2% (n = 19) for stage 0, 18.7% (n = 25) for stage I to II, 44.0% (n = 59) for stage III to IV, and 23.1% (n = 31) for stage V to VI. Prevalence of cerebrovascular disease at autopsy was 59.3% (n = 80), which included any types of infarctions (n = 73) and hemorrhages (n = 10).

As shown in table 2, we compared the age- and sex-adjusted mean (or geometric mean) values of diabetes-related factors among groups according to CERAD score for NPs or Braak stage for NFTs. The subjects with NPs (CERAD score 1 to 3) showed significantly higher levels of 2-hour PG, fasting insulin, and HOMA-IR than those without NPs (CERAD score 0). However, there was no obvious dose-response relationship between these variables and CERAD score. The FPG levels remained broadly constant irrespective of CERAD score. Regarding the frequencies of NFTs, we found no relationship between any diabetes-related factor and Braak stage.

As shown in table 3, we estimated the effect of each diabetes-related factor on the presence of AD pathology using logistic regression analysis. As for NPs, elevated 2-hour PG significantly increased the risk of NPs in the age- and sex-adjusted analysis (model 1). Similarly, hyperinsulinemia and high HOMA-IR were also significant positive risk factors

Table 2   Age- and sex-adjusted means of glucose, insulin, and HOMA-IR according to CERAD score and Braak stage[a]

	Frequency of NPs (CERAD score)				p Value (CERAD score 1–3 vs 0)	Frequency of NFTs (Braak stage)				p Value (Braak stage I–IV vs 0)
	0	1	2	3		0	I, II	III, IV	V, VI	
Fasting plasma glucose, mmol/L	5.7	6.0	6.2	5.9	0.22	5.7	6.1	5.8	6.0	0.38
2-hour post-load plasma glucose, mmol/L	7.2	9.0[c]	9.6[b]	8.7	0.03	7.0	9.2[c]	8.4	8.5	0.13
Fasting insulin, μU/mL	4.6	6.1[b]	5.2	5.6[c]	0.03	5.1	5.0	5.2	5.7	0.81
HOMA-IR	1.2	1.6[b]	1.4	1.4[c]	0.02	1.3	1.4	1.3	1.5	0.62

Abbreviations: CERAD = Consortium to Establish a Registry for Alzheimer's Disease; HOMA-IR = homeostasis model assessment of insulin resistance; NP = neuritic plaque.
[a] Geometric means for fasting insulin and HOMA-IR are shown due to their skewed distributions.
[b] $p < 0.05$, [c] $p < 0.10$ vs CERAD score = 0 or Braak stage = 0.

Table 3 Odds ratios and 95% confidence intervals for the presence vs absence of neuritic plaques and neurofibrillary tangles[a]

	OR for presence of NPs (CERAD score 1–3 vs 0)				OR for presence of NFTs (Braak stage I–VI vs 0)			
	Model 1		Model 2		Model 1		Model 2	
	OR (95% CI)	p Value	OR (95% CI)	p Value	OR (95% CI)	p Value	OR (95% CI)	p Value
Fasting plasma glucose, mmol/L	1.33 (0.86–2.04)	0.20	1.41 (0.88–2.26)	0.15	1.31 (0.72–2.37)	0.38	1.35 (0.74–2.47)	0.33
2-hour post-load plasma glucose, mmol/L	1.66 (1.04–2.63)	0.03	1.71 (1.04–2.80)	0.03	1.58 (0.85–2.93)	0.15	1.67 (0.88–3.17)	0.12
Fasting insulin, μU/mL	1.61 (1.04–2.48)	0.03	2.03 (1.11–3.70)	0.02	1.05 (0.62–1.79)	0.85	1.06 (0.55–2.04)	0.86
HOMA-IR	1.67 (1.08–2.59)	0.02	2.11 (1.18–3.79)	0.01	1.14 (0.66–1.98)	0.64	1.19 (0.62–2.30)	0.60

Abbreviations: CERAD = Consortium to Establish a Registry for Alzheimer's Disease; CI = confidence interval; HOMA-IR = homeostasis model assessment of insulin resistance; NP = neuritic plaque; NFT = neurofibrillary tangle; OR = odds ratio.
[a] Model 1: adjusted for age and sex. Model 2: adjusted for age, sex, systolic blood pressure, total cholesterol, body mass index, current smoking, regular exercise, and cerebrovascular disease. ORs are given for each 1-SD increase in glucose, or log fasting insulin and HOMA-IR values.

for NPs. However, there was no relationship between FPG and NPs. These results were almost the same in the multivariate analyses after adjustment for age, sex, systolic blood pressure, total cholesterol, BMI, current smoking, regular exercise, and cerebrovascular disease (model 2). We repeated analyses after excluding the 21 cases with cognitive impairment, and the associations remained unchanged. On the other hand, we found no significant association between diabetes-related factors and NFT pathology (Braak stage I to VI vs stage 0).

To confirm the association between diabetes-related factors and NPs, we compared the risk of NPs among tertiles of 2-hour PG, fasting insulin, and HOMA-IR (figure 1). Compared with the lowest

tertile of 2-hour PG (<5.9 mmol/L), the risk of NPs was significantly increased in the highest tertile (>8.6 mmol/L) after adjustment for age and sex (model 1). After adjustment for the aforementioned confounding factors (model 2), this relationship was marginally significant. On the other hand, the highest tertiles of fasting insulin (>6 μU/mL) and HOMA-IR (>1.77) showed increased risk for NPs compared with the lowest tertiles (<4 μU/mL for insulin, <0.97 for HOMA-IR) in models 1 and 2.

Finally, we examined the combined effects of *APOE* genotype and the magnitude of the diabetes-related factors on the risk of NP pathology (figure 2). For example, the subjects were classified into the following 4 groups according to the 2-hour PG level

Figure 1 Odds ratios for each tertile of glucose (A), insulin (B), and HOMA-IR (C) vs the lowest tertile for the presence of neuritic plaques

Model 1: adjusted for age and sex. Model 2: adjusted for age, sex, systolic blood pressure, total cholesterol, body mass index, current smoking, regular exercise, and cerebrovascular disease. *p < 0.05, **p < 0.10 vs the lowest tertile. HOMA-IR = homeostasis model assessment of insulin resistance.

—216—

Figure 2 Odds ratios for the presence of neuritic plaques according to diabetes-related risk factors and APOE genotype

Adjusted for age, sex, and total cholesterol. The numbers in the figure are odds ratios vs the reference group (APOE ε4 noncarrier and lower level of glucose [A], insulin [B], or HOMA-IR [C]). *p < 0.05 vs reference group. 2hPG = 2-hour post-load plasma glucose; HOMA-IR = homeostasis model assessment of insulin resistance.

and *APOE* status: low 2-hour PG (lowest and second tertiles, ≤8.6 mmol/L) and noncarriers of *APOE* ε4 (group 1), high 2-hour PG (highest tertile, >8.6 mmol/L) and noncarriers of *APOE* ε4 (group 2), low 2-hour PG and *APOE* ε4 carriers (group 3), and high 2-hPG and *APOE* ε4 carriers (group 4). The ORs for the presence of NPs in these 4 groups were 1.0 in group 1 (reference), 1.5 in group 2, 19.7 in group 3, and 38.0 in group 4. As a result, the coexistence of hyperglycemia and *APOE* ε4 genotype (group 4) was associated with the greatest risk for NPs. We performed similar analyses with fasting insulin and HOMA-IR, and similar patterns were observed.

DISCUSSION We suggest that hyperglycemia, hyperinsulinemia, and insulin resistance are risk factors for NP pathology in AD, and might affect the initiation of NP formation. The lack of a dose-response relationship, and the absence of a significant association between the diabetes-related factors and NFT pathology, might be due to an epidemiologic competing effect, indicating that subjects with very high diabetes-related factors at the clinical examination in 1988 probably died earlier as a result of cardiovascular disease, for example. Nevertheless, NFT pathology was less associated with diabetes-related factors, and NFT pathology is considered to be a consequence of β-amyloid deposition in the amyloid cascade hypothesis.[24] The diabetes-related factors may act upstream of the cascade, and might trigger the AD pathogenesis.

Type 2 diabetes is based on insulin resistance and involves chronic compensatory hyperinsulinemia and hyperglycemia. Insulin itself may affect amyloid metabolism, which leads to NP formation. An impaired insulin signaling may exacerbate β-amyloid accumulation by a weakened inhibition on glycogen synthase kinase 3 (GSK3), which is thought to be critically involved in

AD pathogenesis.[25] Activated GSK3 triggers γ-secretase activity[26] and increases β-amyloid production.[27] Alternatively, excessive β-amyloid can be cleared by endocytosis or through direct extracellular proteolytic degradation by insulin-degrading enzyme (IDE).[28] Insulin seems to inhibit the extracellular degradation of β-amyloid by competition for IDE.[29] Furthermore, several lines of evidence suggest that the toxic effects of hyperglycemia can lead to slowly progressive functional and structural abnormalities in the brain.[30] It is possible that vascular factors induced by metabolic disturbance may modify the AD-related pathology, however, the positive association between diabetes-related factors and NP pathology still remained even after the adjustment for cerebrovascular lesions in our study.

On the contrary, insulin is known to facilitate memory in normal physiology, as demonstrated when administered at optimal doses and in the context of sufficient glucose availability.[31] The formation of NPs, as described above, is a hallmark of AD, which refers to the pathologic entity; meanwhile, Alzheimer dementia, which refers to clinical dementia, may also be caused in part by deficiencies in intracellular and intercellular signaling.[32] Insulin resistance affects insulin signaling, which might lead to a decline in cognitive function. In this study, the subjects who developed Alzheimer dementia were far less than those who manifested NPs (n = 21 vs 88); therefore, the present pathology-based study should overlap, but is also distinct from the previously reported clinicoepidemiologic studies.[2,4,5,8,9] Our target in this study was to evaluate how diabetes affects the neuropathologic process of AD, which would precede the cognitive decline.

Four previous studies have examined the association between diabetes and AD-related pathology, but their results are inconsistent.[5,33-35] Of these, the Honolulu-

—217—

Asia Aging Study was the only population-based study and reported that participants with type 2 diabetes and the *APOE* ε4 allele had a higher number of hippocampal NPs and NFTs in the cortex and hippocampus than those without diabetes and the ε4 allele.[5] In our study, the combination of the unfavorable status afforded by the diabetes-related factors and the presence of the ε4 allele was associated with NP formation, but not with NFT formation (data not shown). The discrepancy in these studies may reflect differences in design of these studies. One possibility is the difference in the observation period between the evaluation of diabetes and the autopsy. Because the observation period in our study was relatively long (10–15 years) compared with the Honolulu-Asia Aging Study (<8 years), our study design might reduce the possibility of reverse causality that the presence of AD might affect lifestyle of the subjects and the severity of glucose intolerance. Another possibility is the difference in the study subjects. Both studies were population-based and included Asian subjects; however, the mean age at clinical examination of the Honolulu-Asia Aging Study (78 years) was greater than that in our study. The other 3 studies[33-35] reported controversial or statistically insignificant results between diabetes status and AD pathology, probably due to the facility-based design and different races.

Our study suggests that the combination of each diabetes-related factor and the *APOE* ε4 genotype may have a synergistic effect on the risk of NPs, even though we failed to show a statistically positive interaction (*p* for interaction = 0.90 [2-hour PG], 0.84 [fasting insulin], 0.79 [HOMA-IR]). The Honolulu-Asia Aging Study[5] also showed synergistic effects of diabetes and the *APOE* ε4 genotype on AD pathology; however, that study did not account for some diabetes-related factors such as insulin levels and HOMA-IR. It was found that apolipoprotein E2 and E3, but not E4, may be involved in β-amyloid clearance.[36] Additionally, apolipoprotein E is commonly colocalized with β-amyloid in NPs,[37] which led to the hypothesis that apolipoprotein E may be involved in β-amyloid aggregation and plaque formation. Because the apolipoprotein E4 isoform stimulates the nucleation and aggregation of β-amyloid in an isoform-specific manner and does not significantly affect the accumulation of β-amyloid deposits,[38] both apolipoprotein E4 and diabetes-related factors may act synergistically on the initiation of β-amyloid aggregation. We consider that a future study using a larger sample size is needed to investigate the interaction between each diabetes-related factor and the *APOE* genotype on the risk of AD pathology.

There are some limitations to our present study. First, the crude, semiquantitative evaluation of NPs (CERAD) and NFTs (Braak stage) could affect the statistical analyses. Second, the medical history of diabetes, such as disease duration, glucose control, and complications, were not considered in this study. Despite these limitations, our study has several strengths. We included community-based subjects, who had detailed metabolic characterization at midlife based on comprehensive blood testing, which included 75-g OGTT profiles and fasting insulin levels, and we systematically assessed AD pathology. Accordingly, the data included in this study are of value to examine the metabolic risk factors for AD pathology. In the Hisayama Study, both participation rate of clinical examinations and autopsy rate have remained at high levels. Therefore, our results could apply to other Japanese populations.

Further studies are required to determine if there is a causal link between insulin resistance and the development of NPs or other AD-related neuropathologies. In the future, adequate control of diabetes might contribute to a strategy for the prevention of AD.

REFERENCES
1. Allen KV, Frier BM, Strachan MW. The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol 2004;490:169–175.